OncoMatch/Clinical Trials/NCT07222488
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Is NCT07222488 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies MK-3120 for bladder cancer.
Treatment: MK-3120 — Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove the tumor with a procedure called transurethral resection of the bladder tumor (TURBT). Researchers want to learn if using MK-3120, the study medicine, can treat HR NMIBC after TURBT. The goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage CIS
Grade: high-risk
Prior therapy
Must have received: Bacillus Calmette-Guérin (BCG)
Is either: a) Bacillus Calmette-Guérin (BCG)-naïve, defined as either having never received BCG or having received BCG more than 2 years before CIS +/- papillary high-risk NMIBC recurrence. Recurrence must be at least 24 months from the last exposure to BCG with evidence of complete response during the 2-year period post-BCG OR; b) BCG-exposed and received adequate BCG therapy and had recurrence of CIS +/- papillary high-risk NMIBC >12 months but ≤24 months after the last BCG dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Michael G Oefelein Clinical Trials ( Site 0005) · Bakersfield, California
- Carolina Urologic Research Center ( Site 0006) · Myrtle Beach, South Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify